Mycophenolate for early lung scarring in systemic sclerosis
Treatments studied
Part of Lungs & breathing, Skin clinical trials.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent and follow the study plan
- You have systemic sclerosis confirmed by standard medical criteria
- Your recent CT scan shows mild lung scarring (fibrosis in under 20% of the lungs) within the last 12 months
- Your lung function breathing test shows forced vital capacity of at least 80% of predicted within 6 months
- Your interstitial lung disease (lung involvement) started within the last 7 years
- You can speak French or English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This study tests whether a combination of three medicines (azithromycin, hydroxychloroquine, and prednisone) can help people with scarring or inflammation in the lungs caused by certain genetic changes. It aims to see if these drugs can slow down or improve the lung disease.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.